Fighting Back Against Gastrointestinal Stromal Tumors
Read more
To facilitate research and partnership with philanthropic, public agencies or commercial enterprises
LEARN MORE >
Filing and prosecuting patents and protect copyright globally
LEARN MORE >The Bridge Innovation and Business Development (BIBD) office of UMass Chan recently secured an agreement with CANbridge Pharmaceuticals Inc. to license rights to a novel gene therapy for spinal muscular atrophy (SMA). The royalty-bearing, exclusive license for SMA includes a significant upfront payment and potential for an array of developmental and commercial milestones. BIBD previously facilitated an agreement with CANbridge in 2020 to sponsor cutting-edge research on SMA at UMass Chan’s Horae Gene Therapy Center, which produced patentable technology included in the license. Sponsored research on gene therapy for SMA between CANbridge and the Horae Gene Therapy Center is ongoing.
BIBD serves as the hub for all commercialization activities at UMass Chan. The significant return on the license and sponsored research with CANbridge, and others of its kind, supports the thriving research enterprise at UMass Chan and its mission to translate scientific discoveries into real-world, life-saving therapies.
We will quickly gather your project goals and answer any questions you may have to arrange an optimal engagement.
The New Ventures (NV) group is the first point of contact for UMass Chan researchers and external partners alike. This group is responsible for proactively scouting UMass Chan Medical School to identify and evaluate commercializable assets and platform technology and match them with potential partners in biotech, pharma and investor ecosystem.
Keep in touch with news and partnering opportunities from BRIDGE Innovation & Business Development.
Interested in exploring licensing opportunities, investing in a startup, or sponsoring UMass Chan Medical School research?
